MYCAMINE Side Effects

7028173-5 |
on Sep 14, 2010 Male patient from UNITED STATES , 49 years of age, was diagnosed with sepsis (What is sepsis?) and was treated with Mycamine (View Usage). . Mycamine dosage: 300 Mg, /d.

7027466-5 | Circulatory Collapse, Hepatic Failure, Multi-organ Failure, Renal Failure, Respiratory Failure, Septic Shock
Patient was taking Mycamine (View Usage). Patient had the following side effects: circulatory collapse, hepatic failure, multi-organ failure, renal failure, respiratory failure, septic shock on Sep 21, 2010 from FRANCE Additional patient health information: Male patient , 63 years of age, was diagnosed with palliative care (What is palliative care?) and. Mycamine dosage: 100 Mg, /d, Iv Nos.

7018600-1 | Blood Potassium Decreased, Hepatic Failure, Multi-organ Failure, Renal Failure, Septic Shock
Adverse event was reported on Sep 15, 2010 by a Male patient taking Mycamine (View Usage) (Dosage: 100 Mg, Uid/qd, Iv Nos) was diagnosed with candida sepsis and. Location: FRANCE , 53 years of age, weighting 154.3 lb, After Mycamine was administered, patient had the following side effects: blood potassium decreased, hepatic failure, multi-organ failure, renal failure, septic shock. During the same period patient was treated with FLUCYTOSINE (FLUCYTOSINE) (View Flucytosine (flucytosine) Review and Flucytosine (flucytosine) Label ), CLAVENTIN (TICARCILLIN DISODIUM) (View Claventin (ticarcillin Disodium) Review and Claventin (ticarcillin Disodium) Label ), VITAMIN K (VITAMIN K NOS) (View Vitamin K (vitamin K Nos) Review and Vitamin K (vitamin K Nos) Label ), CEFTAZIDIME SODIUM (View Ceftazidime Sodium Review and Ceftazidime Sodium Label ), PRIMAXIN (View Primaxin Review and Primaxin Label ), BUMETANIDE (View Bumetanide Review and Bumetanide Label ), PANTOPRAZOLE SODIUM (View Pantoprazole Sodium Review and Pantoprazole Sodium Label ). Patient was hospitalized.

7003537-4 | Hepatic Failure, Hypovitaminosis, Renal Failure, Sedation, Septic Shock
on Sep 08, 2010 Male patient from FRANCE , 53 years of age, weighting 154.3 lb, was diagnosed with candida sepsis and was treated with Mycamine (View Usage). Patient experienced the following unwanted or unexpected effects: hepatic failure, hypovitaminosis, renal failure, sedation, septic shock. Mycamine dosage: 100 Mg, Uid/qd, Iv Nos. During the same period patient was treated with FLUCYSTOSINE (FLUCUYTOSINE) (View Flucystosine (flucuytosine) Review and Flucystosine (flucuytosine) Label ), CLAVENTIN (TICARCILLIN DISODIUM) (View Claventin (ticarcillin Disodium) Review and Claventin (ticarcillin Disodium) Label ), VITAMIN K (VITAMIN K NOS) (View Vitamin K (vitamin K Nos) Review and Vitamin K (vitamin K Nos) Label ), CEFTAZIDIME SODIUM (View Ceftazidime Sodium Review and Ceftazidime Sodium Label ), PRIMAXIN (View Primaxin Review and Primaxin Label ), BUMETANIDE (View Bumetanide Review and Bumetanide Label ), PANTOPRAZOLE SODIUM (View Pantoprazole Sodium Review and Pantoprazole Sodium Label ). Patient was hospitalized.


6959611-1 | Aspartate Aminotransferase Increased, Blood Alkaline Phosphatase Increased, Blood Bilirubin Increased, Blood Creatinine Increased, Fungal Infection, Gamma-glutamyltransferase Increased, Lung Disorder, Pneumonia Klebsiella, Septic Shock
on Aug 18, 2010 Male patient from FRANCE , 60 years of age, weighting 180.8 lb, was diagnosed with antifungal treatment and was treated with Mycamine (View Usage). Patient had the following side effects: aspartate aminotransferase increased, blood alkaline phosphatase increased, blood bilirubin increased, blood creatinine increased, fungal infection (What is fungal infection?), gamma-glutamyltransferase increased, lung disorder, pneumonia klebsiella, septic shock. Mycamine dosage: 100 Mg, Uid/qd, Iv Nos.

6931239-9 | Aspartate Aminotransferase Increased, Blood Bilirubin Increased, Gamma-glutamyltransferase Increased, Renal Failure Acute, Sepsis
Patient was taking Mycamine (View Usage). After Mycamine was administered, patient had the following side effects: aspartate aminotransferase increased, blood bilirubin increased, gamma-glutamyltransferase increased, renal failure acute, sepsis (What is sepsis?) on Aug 06, 2010 from FRANCE Additional patient health information: Male patient , 55 years of age, weighting 158.7 lb, was diagnosed with prophylaxis and. Mycamine dosage: 50 Mg, Total Dose, Iv Nos. During the same period patient was treated with NOXAFIL (View Noxafil Review and Noxafil Label ).

6929745-6 | Multi-organ Failure, Septic Shock
Adverse event was reported on Aug 03, 2010 by a Male patient taking Mycamine (View Usage) (Dosage: 100 Mg, Uid/qd, Iv Nos) was diagnosed with systemic candida and. Location: FRANCE , 53 years of age, weighting 154.3 lb, Patient experienced the following unwanted or unexpected effects: multi-organ failure, septic shock. During the same period patient was treated with FLUCYTOSINE (FLUCYTOSINE) (View Flucytosine (flucytosine) Review and Flucytosine (flucytosine) Label ).

6919582-0 | Aspartate Aminotransferase Increased, Blood Bilirubin Increased, Cholecystitis Acute, Gamma-glutamyltransferase Increased, Multi-organ Failure, Neutrophil Count Decreased, Renal Failure Acute, Sepsis
on Jul 30, 2010 Male patient from FRANCE , 55 years of age, weighting 158.7 lb, was diagnosed with prophylaxis and was treated with Mycamine (View Usage). Patient had the following side effects: aspartate aminotransferase increased, blood bilirubin increased, cholecystitis acute, gamma-glutamyltransferase increased, multi-organ failure, neutrophil count decreased, renal failure acute, sepsis (What is sepsis?). Mycamine dosage: 50 Mg, Total Dose, Iv Nos. During the same period patient was treated with NOXAFIL (View Noxafil Review and Noxafil Label ).

6915522-9 | Multi-organ Failure, Septic Shock
on Jul 27, 2010 Male patient from FRANCE , 53 years of age, weighting 154.3 lb, was diagnosed with systemic candida and was treated with Mycamine (View Usage). After Mycamine was administered, patient had the following side effects: multi-organ failure, septic shock. Mycamine dosage: 100 Mg, Uid/qd, Iv Nos. During the same period patient was treated with FLUCYTOSINE (FLUCYTOSINE) (View Flucytosine (flucytosine) Review and Flucytosine (flucytosine) Label ).

6895954-8 | Hepatic Encephalopathy
Patient was taking Mycamine (View Usage). Patient experienced the following unwanted or unexpected effects: hepatic encephalopathy on Jul 22, 2010 from UNITED STATES Additional patient health information: Male patient , 37 years of age, weighting 174.2 lb, was diagnosed with candidiasis and. Mycamine dosage: Iv Nos. Patient was hospitalized.

6865989-X | Blood Creatinine Increased, Candidiasis, Culture Positive, Gamma-glutamyltransferase Increased, Pyrexia
Adverse event was reported on Jun 16, 2010 by a Male patient taking Mycamine (View Usage) (Dosage: 50 Mg, Iv Nos) was diagnosed with prophylaxis and. Location: FRANCE , 60 years of age, weighting 260.1 lb, Patient had the following side effects: blood creatinine increased, candidiasis, culture positive, gamma-glutamyltransferase increased, pyrexia.

6846593-6 | Abdominal Pain, Atelectasis, Haematemesis, Haemorrhage, Histiocytosis Haematophagic, Hypertension, Mucormycosis, Pulmonary Haemorrhage, Systemic Lupus Erythematosus
on Jul 01, 2010 Male patient from UNITED STATES , 14 years of age, was diagnosed with peritonitis bacterial, immunosuppression, systemic lupus erythematosus and was treated with Mycamine (View Usage). After Mycamine was administered, patient had the following side effects: abdominal pain (What is abdominal pain?), atelectasis, haematemesis, haemorrhage, histiocytosis haematophagic, hypertension, mucormycosis, pulmonary haemorrhage, systemic lupus erythematosus. Mycamine dosage: 3.5 Mg/kg, Uid/qd, Iv Nos. During the same period patient was treated with PROGRAF (0.06 Mg/kg, Bid, Iv Nos) (View Prograf Review and Prograf Label ), CYCLOPHOSPHAMIDE (750 Mg/m2, Monthly) (View Cyclophosphamide Review and Cyclophosphamide Label ), METHYLPREDNISOLONE (30 Mg/kg, Weekly) (View Methylprednisolone Review and Methylprednisolone Label ), PIPERACILLIN SODIUM W/TRAZOBACTAM (PIPERACILLIN SODIUM, TAZOBACTAM) (View Piperacillin Sodium W/trazobactam (piperacillin Sodium, Tazobactam) Review and Piperacillin Sodium W/trazobactam (piperacillin Sodium, Tazobactam) Label ), GENTAMYCIN (GENTAMYCIN) (View Gentamycin (gentamycin) Review and Gentamycin (gentamycin) Label ), VANCOMYCIN (View Vancomycin Review and Vancomycin Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ), HYDROXYCHLOROQUINE SULFATE (View Hydroxychloroquine Sulfate Review and Hydroxychloroquine Sulfate Label ).

6846522-5 | Overdose
on Jul 01, 2010 Female patient from UNITED STATES , 63 years of age, weighting 110.2 lb, was diagnosed with fungal infection (What is fungal infection?) and was treated with Mycamine (View Usage). Patient experienced the following unwanted or unexpected effects: overdose. Mycamine dosage: 500 Mg, Total Dose.

6818559-3 | Blood Creatinine Increased, Gamma-glutamyltransferase Increased, Neutrophil Count Decreased, Pyrexia
Patient was taking Mycamine (View Usage). Patient had the following side effects: blood creatinine increased, gamma-glutamyltransferase increased, neutrophil count decreased, pyrexia on Jun 16, 2010 from FRANCE Additional patient health information: Male patient , 60 years of age, weighting 260.1 lb, was diagnosed with prophylaxis and. Mycamine dosage: . During the same period patient was treated with FLUCONAZOLE (View Fluconazole Review and Fluconazole Label ).

6816253-6 |
Adverse event was reported on Jun 24, 2010 by a Male patient taking Mycamine (View Usage) (Dosage: See Image, Iv Nos) . Location: UNITED STATES , 28 years of age, . Patient was hospitalized.

6767740-0 | Enterocolitis Infectious
on May 31, 2010 Male patient from FRANCE , 29 years of age, was treated with Mycamine (View Usage). Patient experienced the following unwanted or unexpected effects: enterocolitis infectious. Mycamine dosage: .

6693382-1 |
on Apr 14, 2010 Male patient from UNITED STATES , 56 years of age, was diagnosed with cirrhosis alcoholic and was treated with Mycamine (View Usage). . Mycamine dosage: 50 Mg.

6692943-3 | Aspergillosis, Candida Sepsis, Cytomegalovirus Infection, Enterococcal Sepsis, Fungal Sepsis, Haemodialysis, Infection In An Immunocompromised Host, Multi-organ Failure
Patient was taking Mycamine (View Usage). After Mycamine was administered, patient had the following side effects: aspergillosis, candida sepsis, cytomegalovirus infection (What is cytomegalovirus infection?), enterococcal sepsis, fungal sepsis, haemodialysis, infection in an immunocompromised host, multi-organ failure on Apr 14, 2010 from FRANCE Additional patient health information: Male patient , 52 years of age, weighting 198.4 lb, was diagnosed with antifungal prophylaxis, prophylaxis against transplant rejection and. Mycamine dosage: 100 Mg, Uid/qd, Iv Nos. During the same period patient was treated with NEORAL (View Neoral Review and Neoral Label ), SIMULECT (View Simulect Review and Simulect Label ), .............. (View .............. Review and .............. Label ), SOLU MEDROL (View Solu-medrol Review and Solu-medrol Label ), VALGANCICLOVIR HCL (View Valganciclovir Hcl Review and Valganciclovir Hcl Label ), CLAVENTIN (TICARCILLIN DISODIUM) (View Claventin (ticarcillin Disodium) Review and Claventin (ticarcillin Disodium) Label ), NOREPINEPHRINE BITARTRATE (View Norepinephrine Bitartrate Review and Norepinephrine Bitartrate Label ).

6686636-6 | Acinetobacter Infection, Haemodialysis, Ileus, Jaundice, Malnutrition, Pneumonia, Proteus Infection, Renal Failure Chronic, Small Intestinal Obstruction
Adverse event was reported on Apr 05, 2010 by a Female patient taking Mycamine (View Usage) (Dosage: 100 Mg, Uid/qd,) was diagnosed with systemic candida and. Location: UNITED STATES , 94 years of age, Patient experienced the following unwanted or unexpected effects: acinetobacter infection, haemodialysis, ileus, jaundice (What is jaundice?), malnutrition, pneumonia (What is pneumonia?), proteus infection, renal failure chronic, small intestinal obstruction.

6657731-2 | Candida Sepsis, Enterococcal Infection, Fungal Sepsis, Haemodialysis, Lung Disorder, Multi-organ Failure, Renal Failure, Respiratory Tract Infection, Stenotrophomonas Infection
on Mar 17, 2010 Male patient from FRANCE , 52 years of age, weighting 198.4 lb, was diagnosed with antifungal prophylaxis, liver transplant (What is liver transplant?) and was treated with Mycamine (View Usage). Patient had the following side effects: candida sepsis, enterococcal infection, fungal sepsis, haemodialysis, lung disorder, multi-organ failure, renal failure, respiratory tract infection, stenotrophomonas infection. Mycamine dosage: 100 Mg, Uid/qd, Iv Nos. During the same period patient was treated with NEORAL (View Neoral Review and Neoral Label ), SIMULECT (View Simulect Review and Simulect Label ), SOLU MEDROL (View Solu-medrol Review and Solu-medrol Label ), VALGANCICLOVIR HCL (View Valganciclovir Hcl Review and Valganciclovir Hcl Label ), CLAVENTIN (TICARCILLIN DISODIUM) (View Claventin (ticarcillin Disodium) Review and Claventin (ticarcillin Disodium) Label ), NOREPINEPHRINE BITARTRATE (View Norepinephrine Bitartrate Review and Norepinephrine Bitartrate Label ).

6618428-8 | Acute Graft Versus Host Disease In Liver, Blood Bilirubin Increased, Blood Creatine Increased, Blood Glucose Increased, Blood Potassium Decreased, Cardiopulmonary Failure, Haemoglobin Decreased, Hepatic Failure, Platelet Count Decreased
on Feb 13, 2009 Male patient from UNITED STATES , 39 years of age, was diagnosed with aspergillosis and was treated with Mycamine (View Usage). After Mycamine was administered, patient had the following side effects: acute graft versus host disease in liver, blood bilirubin increased, blood creatine increased, blood glucose increased, blood potassium decreased, cardiopulmonary failure, haemoglobin decreased, hepatic failure, platelet count decreased. Mycamine dosage: 150 Mg, Uid/qd. During the same period patient was treated with CELLCEPT (View Cellcept Review and Cellcept Label ), PROGRAF (View Prograf Review and Prograf Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ), SIROLIMUS (RAPAMUNE) (View Sirolimus (rapamune) Review and Sirolimus (rapamune) Label ), ABELCET (View Abelcet Review and Abelcet Label ), VFEND (View Vfend Review and Vfend Label ). Patient was hospitalized and became disabled.

6579045-1 | Disease Complication, Haematemesis, Infection, Multi-organ Failure, Off Label Use, Renal Disorder
Patient was taking Mycamine (View Usage). Patient experienced the following unwanted or unexpected effects: disease complication, haematemesis, infection (What is infection?), multi-organ failure, off label use, renal disorder on Jan 27, 2010 from FRANCE Additional patient health information: Male patient , child 12 years of age, was diagnosed with oesophageal candidiasis and. Mycamine dosage: . During the same period patient was treated with VORICONAZOLE (View Voriconazole Review and Voriconazole Label ), AMBISOME (View Ambisome Review and Ambisome Label ).

6210883-0 | Cardio-respiratory Arrest, Lactic Acidosis
Adverse event was reported on May 18, 2009 by a Female patient taking Mycamine (View Usage) (Dosage: 100 Mg, Uid/qd) was diagnosed with prophylaxis and. Location: UNITED STATES , 39 years of age, Patient had the following side effects: cardio-respiratory arrest, lactic acidosis. Patient was hospitalized.

6181173-X | Rash Erythematous, Systemic Inflammatory Response Syndrome
on Apr 22, 2009 Female patient from UNITED KINGDOM , child 2 years of age, was diagnosed with candidiasis and was treated with Mycamine (View Usage). After Mycamine was administered, patient had the following side effects: rash erythematous, systemic inflammatory response syndrome. Mycamine dosage: . During the same period patient was treated with AMBISOME (View Ambisome Review and Ambisome Label ).

6178682-6 | Blood Pressure Systolic Decreased, Cardiovascular Disorder, Dysphagia, Gallbladder Disorder, Haematocrit Decreased, Haemoglobin Decreased, Myelodysplastic Syndrome, Sepsis, Tachycardia
on Apr 23, 2009 Male patient from UNITED STATES , 75 years of age, weighting 209.7 lb, was treated with Mycamine (View Usage). Patient experienced the following unwanted or unexpected effects: blood pressure systolic decreased, cardiovascular disorder, dysphagia, gallbladder disorder, haematocrit decreased, haemoglobin decreased, myelodysplastic syndrome, sepsis (What is sepsis?), tachycardia. Mycamine dosage: . During the same period patient was treated with MEGACE (View Megace Review and Megace Label ), PROCRIT (View Procrit Review and Procrit Label ), CEFEPIME (View Cefepime Review and Cefepime Label ), NOREPINEPHRINE (NOREPINEPHRINE HYDROCHLORIDE) (View Norepinephrine (norepinephrine Hydrochloride) Review and Norepinephrine (norepinephrine Hydrochloride) Label ), PROTONIX (View Protonix Review and Protonix Label ), DIPRIVAN (View Diprivan Review and Diprivan Label ), PIPERACILLIN/TAZO. (PIPERACILLIN SODIUM, TAZOBACTAM SODIUM) (View Piperacillin/tazo. (piperacillin Sodium, Tazobactam Sodium) Review and Piperacillin/tazo. (piperacillin Sodium, Tazobactam Sodium) Label ), ALBUTEROL (View Albuterol Review and Albuterol Label ). Patient was hospitalized.

6153759-X | Haematocrit Decreased, Haemoglobin Decreased, Sepsis, Weight Decreased
Patient was taking Mycamine (View Usage). Patient had the following side effects: haematocrit decreased, haemoglobin decreased, sepsis (What is sepsis?), weight decreased on Apr 04, 2009 from UNITED STATES Additional patient health information: Male patient , 75 years of age, weighting 209.7 lb, . Mycamine dosage: . During the same period patient was treated with PROCRIT (View Procrit Review and Procrit Label ), CEFEPIME (View Cefepime Review and Cefepime Label ), NOREPINEPHRINE (NOREPINEPHRINE HYDROCHLORIDE) (View Norepinephrine (norepinephrine Hydrochloride) Review and Norepinephrine (norepinephrine Hydrochloride) Label ), PROTONIX (View Protonix Review and Protonix Label ), DIPRIVAN (View Diprivan Review and Diprivan Label ), PIPERACILLIN/TAZO. (PIPERACILLIN SODIUM, TAZOBACTAM SODIUM) (View Piperacillin/tazo. (piperacillin Sodium, Tazobactam Sodium) Review and Piperacillin/tazo. (piperacillin Sodium, Tazobactam Sodium) Label ), ALBUTEROL (View Albuterol Review and Albuterol Label ), SIMVASTATIN (View Simvastatin Review and Simvastatin Label ).

6086977-X | Bronchopulmonary Aspergillosis, Chest Pain, Cholecystitis, Cholecystitis Acute, Deep Vein Thrombosis, Enterococcal Bacteraemia, Fall, Femoral Neck Fracture, Haemodialysis
Adverse event was reported on Feb 11, 2009 by a Male patient taking Mycamine (View Usage) (Dosage: 150 Mg, Uid/qd; 150 Mg, Uid/qd, Iv Nos) was diagnosed with lung transplant (What is lung transplant?) and. Location: UNITED STATES , 58 years of age, After Mycamine was administered, patient had the following side effects: bronchopulmonary aspergillosis, chest pain (What is chest pain?), cholecystitis, cholecystitis acute, deep vein thrombosis (What is deep vein thrombosis?), enterococcal bacteraemia, fall (What is fall?), femoral neck fracture, haemodialysis. During the same period patient was treated with PROGRAF (View Prograf Review and Prograf Label ). Patient was hospitalized.

6057877-6 | Acute Graft Versus Host Disease In Liver, Cardiopulmonary Failure, Hepatic Failure, Therapeutic Response Decreased, Treatment Noncompliance
on Jan 13, 2009 Male patient from UNITED STATES , 39 years of age, was diagnosed with aspergillosis and was treated with Mycamine (View Usage). Patient experienced the following unwanted or unexpected effects: acute graft versus host disease in liver, cardiopulmonary failure, hepatic failure, therapeutic response decreased, treatment noncompliance. Mycamine dosage: 150 Mg, Uid/qd,. During the same period patient was treated with CELLCEPT (View Cellcept Review and Cellcept Label ), PROGRAF (View Prograf Review and Prograf Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ), SIROLIMUS (SIROLIMUS) (View Sirolimus (sirolimus) Review and Sirolimus (sirolimus) Label ), ABELCET (View Abelcet Review and Abelcet Label ), VFEND (View Vfend Review and Vfend Label ). Patient was hospitalized and became disabled.

6008995-X | Acute Graft Versus Host Disease In Liver, Aspartate Aminotransferase Increased, Blood Alkaline Phosphatase Increased, Blood Bilirubin Increased, Therapeutic Response Unexpected
on Dec 02, 2008 Male patient from UNITED STATES , 39 years of age, was diagnosed with aspergillosis and was treated with Mycamine (View Usage). Patient had the following side effects: acute graft versus host disease in liver, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood bilirubin increased, therapeutic response unexpected. Mycamine dosage: 150 Mg, Uid/qd. During the same period patient was treated with ABELCET (View Abelcet Review and Abelcet Label ), VFEND (View Vfend Review and Vfend Label ). Patient was hospitalized and became disabled.

5965288-4 | Acute Respiratory Distress Syndrome, Hodgkin's Disease, Pneumonia
Patient was taking Mycamine (View Usage). After Mycamine was administered, patient had the following side effects: acute respiratory distress syndrome, hodgkin's disease (What is hodgkin's disease?), pneumonia (What is pneumonia?) on Nov 06, 2008 from UNITED STATES Additional patient health information: Female patient , 51 years of age, . Mycamine dosage: .

5917013-0 | Acute Respiratory Distress Syndrome, Hodgkin's Disease
Adverse event was reported on Sep 24, 2008 by a Female patient taking Mycamine (View Usage) (Dosage: ) . Location: UNITED STATES , 51 years of age, Patient experienced the following unwanted or unexpected effects: acute respiratory distress syndrome, hodgkin's disease (What is hodgkin's disease?).

5812322-8 |
on Jul 03, 2008 Male patient from UNITED STATES , 55 years of age, was diagnosed with candidiasis and was treated with Mycamine (View Usage). . Mycamine dosage: .

5764181-X |
on Jun 02, 2008 Female patient from UNITED STATES , 51 years of age, was treated with Mycamine (View Usage). . Mycamine dosage: .

5727987-9 | Acidosis, Acute Prerenal Failure, Alanine Aminotransferase Increased, Anaemia, Aspartate Aminotransferase Increased, Bacterial Infection, Bladder Neoplasm, Blood Alkaline Phosphatase Increased, Blood Bilirubin Increased
Patient was taking Mycamine (View Usage). Patient experienced the following unwanted or unexpected effects: acidosis, acute prerenal failure, alanine aminotransferase increased, anaemia, aspartate aminotransferase increased, bacterial infection (What is bacterial infection?), bladder neoplasm, blood alkaline phosphatase increased, blood bilirubin increased on Apr 21, 2008 from UNITED STATES Additional patient health information: Male patient , 74 years of age, was diagnosed with fungal infection (What is fungal infection?) and. Mycamine dosage: 100 Mg, Uid/qd, 150 Mg, Uid, Qd, 100 Mg, Uig, Qd. During the same period patient was treated with DIFLUCAN (View Diflucan Review and Diflucan Label ).

5720952-7 | Blood Culture Positive, Parainfluenzae Virus Infection, Pneumonia Fungal, Scrotal Pain, Sinusitis, Staphylococcal Infection
Adverse event was reported on Apr 17, 2008 by a Male patient taking Mycamine (View Usage) (Dosage: Other) was diagnosed with bronchopulmonary aspergillosis and. Location: UNITED STATES , 38 years of age, Patient had the following side effects: blood culture positive, parainfluenzae virus infection, pneumonia fungal, scrotal pain, sinusitis (What is sinusitis?), staphylococcal infection (What is staphylococcal infection?). During the same period patient was treated with AMBISOME (5 Mg/kg, Uid/qd,) (View Ambisome Review and Ambisome Label ), IMIPENEM (IMIPENEM) (View Imipenem (imipenem) Review and Imipenem (imipenem) Label ), VANCOMYCIN HYDROCHLORIDE (View Vancomycin Hydrochloride Review and Vancomycin Hydrochloride Label ), VORICONAZOLE (VORICONAZOLE) (View Voriconazole (voriconazole) Review and Voriconazole (voriconazole) Label ).

5716140-0 | Hepatic Enzyme Abnormal
on Jan 09, 2008 Male patient from UNITED STATES , 76 years of age, was treated with Mycamine (View Usage). After Mycamine was administered, patient had the following side effects: hepatic enzyme abnormal. Mycamine dosage: .

5712288-5 |
on Apr 10, 2008 Female patient from UNITED STATES , 48 years of age, was treated with Mycamine (View Usage). . Mycamine dosage: .

5710528-X |
Patient was taking Mycamine (View Usage). on Apr 08, 2008 from UNITED STATES Additional patient health information: Female patient , 32 years of age, . Mycamine dosage: .

5705874-X | Acidosis, Anaemia, Bacteraemia, Blood Culture Positive, Catheter Sepsis, Confusional State, Ejection Fraction Decreased, Fungal Infection, Haemodialysis
Adverse event was reported on Apr 03, 2008 by a Male patient taking Mycamine (View Usage) (Dosage: 100 Mg, Uid/qd,; 150 Mg, Uid/qd,; 100 Mg, Uid/qd,) was diagnosed with fungal infection (What is fungal infection?) and. Location: UNITED STATES , 74 years of age, After Mycamine was administered, patient had the following side effects: acidosis, anaemia, bacteraemia, blood culture positive, catheter sepsis, confusional state, ejection fraction decreased, fungal infection (What is fungal infection?), haemodialysis. During the same period patient was treated with DIFLUCAN (View Diflucan Review and Diflucan Label ).

5638261-3 | Atrial Fibrillation, Chronic Respiratory Failure, Gastrointestinal Disorder, Hypotension, Multi-organ Failure, Muscular Weakness, Myelopathy, Nosocomial Infection, Platelet Count Decreased
on Feb 15, 2008 Female patient from UNITED STATES , 75 years of age, was diagnosed with bronchopulmonary aspergillosis and was treated with Mycamine (View Usage). Patient experienced the following unwanted or unexpected effects: atrial fibrillation (What is atrial fibrillation?), chronic respiratory failure, gastrointestinal disorder, hypotension, multi-organ failure, muscular weakness, myelopathy, nosocomial infection, platelet count decreased. Mycamine dosage: 150 Mg, Uid/qd, Iv Nos. During the same period patient was treated with VORICONAZOLE (VORICONAZOLE) (View Voriconazole (voriconazole) Review and Voriconazole (voriconazole) Label ).

5619526-8 | Alopecia, Renal Failure
on Sep 24, 2007 Male patient from UNITED STATES , weighting 2.87 lb, was treated with Mycamine (View Usage). Patient had the following side effects: alopecia, renal failure. Mycamine dosage: 20 Mg, Uid/qd, Iv Nos. During the same period patient was treated with FLUCONAZOLE (View Fluconazole Review and Fluconazole Label ), DOPAMINE HCL (View Dopamine Hcl Review and Dopamine Hcl Label ), DOBUTAMINE (DOBUTAMINE) (View Dobutamine (dobutamine) Review and Dobutamine (dobutamine) Label ), LASIX (View Lasix Review and Lasix Label ), HYDROCORTISONE (View Hydrocortisone Review and Hydrocortisone Label ), MORPHINE (View Morphine Review and Morphine Label ), LORAZEPAM (View Lorazepam Review and Lorazepam Label ), PANCURONIUM (View Pancuronium Review and Pancuronium Label ).

5619127-1 | Hepatotoxicity, Nephropathy Toxic
Patient was taking Mycamine (View Usage). After Mycamine was administered, patient had the following side effects: hepatotoxicity, nephropathy toxic on Jan 28, 2008 from UNITED STATES Additional patient health information: Female patient , 36 years of age, was diagnosed with aspergillosis and. Mycamine dosage: 150 Mg, Uid/qd. During the same period patient was treated with VORICONAZLOLE (VORICONAZOLE) (View Voriconazlole (voriconazole) Review and Voriconazlole (voriconazole) Label ). Patient was hospitalized.

5586206-7 | Acidosis, Alanine Aminotransferase Increased, Anaemia, Aspartate Aminotransferase Increased, Bacterial Infection, Blood Alkaline Phosphatase Increased, Blood Bilirubin Increased, Blood Culture Positive, Catheter Sepsis
Adverse event was reported on Dec 21, 2007 by a Male patient taking Mycamine (View Usage) (Dosage: 100 Mg, Uid Qd; 150 Mg, Uid/qd, 100 Mg Uid, Qd) was diagnosed with fungal infection (What is fungal infection?) and. Location: UNITED STATES , 74 years of age, Patient experienced the following unwanted or unexpected effects: acidosis, alanine aminotransferase increased, anaemia, aspartate aminotransferase increased, bacterial infection (What is bacterial infection?), blood alkaline phosphatase increased, blood bilirubin increased, blood culture positive, catheter sepsis. During the same period patient was treated with DIFLUCAN (View Diflucan Review and Diflucan Label ).

5579001-6 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Bladder Neoplasm, Blood Alkaline Phosphatase Increased, Blood Bilirubin Increased, Candidiasis
on Dec 17, 2007 Male patient from UNITED STATES , 74 years of age, was diagnosed with fungal infection (What is fungal infection?) and was treated with Mycamine (View Usage). Patient had the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, bladder neoplasm, blood alkaline phosphatase increased, blood bilirubin increased, candidiasis. Mycamine dosage: 100 Mg, Uid/qd,; 150 Mg, Uid/qd,; 100 Mg, Uid/qd,. During the same period patient was treated with FLUCONAZOLE (View Fluconazole Review and Fluconazole Label ).

5491447-3 | Nephrogenic Diabetes Insipidus
on Oct 09, 2007 Male patient from UNITED STATES , 69 years of age, was treated with Mycamine (View Usage). After Mycamine was administered, patient had the following side effects: nephrogenic diabetes insipidus. Mycamine dosage: Parenteral.

5491446-1 | No Therapeutic Response
Patient was taking Mycamine (View Usage). Patient experienced the following unwanted or unexpected effects: no therapeutic response on Oct 09, 2007 from UNITED STATES Additional patient health information: Male patient , 35 years of age, was diagnosed with mucormycosis and. Mycamine dosage: . During the same period patient was treated with AMPHOTERICIN B (View Amphotericin B Review and Amphotericin B Label ), POSACONAZOLE (View Posaconazole Review and Posaconazole Label ).

5490421-0 | Alopecia, Renal Failure
Adverse event was reported on Aug 17, 2007 by a Female patient taking Mycamine (View Usage) (Dosage: 20 Mg, Uid/qd, Iv Nos) . Location: UNITED STATES , weighting 2.87 lb, Patient had the following side effects: alopecia, renal failure. During the same period patient was treated with FLUCONAZOLE (View Fluconazole Review and Fluconazole Label ), DOPAMINE HCL (View Dopamine Hcl Review and Dopamine Hcl Label ), DOBUTAMINE (DOBUTAMINE) (View Dobutamine (dobutamine) Review and Dobutamine (dobutamine) Label ), LASIX (View Lasix Review and Lasix Label ), HYDROCORTISONE (View Hydrocortisone Review and Hydrocortisone Label ), MORPHINE (View Morphine Review and Morphine Label ), LORAZEPAM (View Lorazepam Review and Lorazepam Label ), PANCURONIUM (View Pancuronium Review and Pancuronium Label ).

5479357-9 | Sepsis
on Sep 25, 2007 Male patient from UNITED STATES , 50 years of age, was diagnosed with prophylaxis and was treated with Mycamine (View Usage). After Mycamine was administered, patient had the following side effects: sepsis (What is sepsis?). Mycamine dosage: 100 Mg.

5457524-8 | Abdominal Sepsis, Antimicrobial Susceptibility Test Resistant, Cardiac Valve Vegetation, Systemic Candida
on Sep 04, 2007 Female patient from UNITED STATES , 47 years of age, was diagnosed with systemic candida and was treated with Mycamine (View Usage). Patient experienced the following unwanted or unexpected effects: abdominal sepsis, antimicrobial susceptibility test resistant, cardiac valve vegetation, systemic candida. Mycamine dosage: 150 Mg, Uid/qd,. During the same period patient was treated with CASPOFUNGIN(CASPOFUNGIN) (50 Mg, Uid/qd,) (View Caspofungin(caspofungin) Review and Caspofungin(caspofungin) Label ). Patient was hospitalized.

5363561-4 | Aspartate Aminotransferase Increased, Large Intestine Perforation, Liver Disorder, Peritonitis, Septic Shock
Patient was taking Mycamine (View Usage). Patient had the following side effects: aspartate aminotransferase increased, large intestine perforation, liver disorder, peritonitis, septic shock on Jun 18, 2007 from UNITED STATES Additional patient health information: Male patient , weighting 231.5 lb, was diagnosed with evidence based treatment, fungal infection (What is fungal infection?) and. Mycamine dosage: 150 Mg Q24hr Iv.